Pharmacological Targeting of MTHFD2 Suppresses Acute Myeloid Leukemia by Inducing Thymidine Depletion and Replication Stress

The folate metabolism enzyme MTHFD2 (methylenetetrahydrofolate dehydrogenase/cyclohydrolase) is consistently overexpressed in cancer but its roles are not fully characterized, and current candidate inhibitors have limited potency for clinical development. In the present study, we demonstrate a role for MTHFD2 in DNA replication and genomic stability in cancer cells, and perform a drug screen to identify potent and selective nanomolar MTHFD2 inhibitors; protein cocrystal structures demonstrated binding to the active site of MTHFD2 and target engagement. MTHFD2 inhibitors reduced replication fork speed and induced replication stress followed by S-phase arrest and apoptosis of acute myeloid leukemia cells in vitro and in vivo, with a therapeutic window spanning four orders of magnitude compared with nontumorigenic cells. Mechanistically, MTHFD2 inhibitors prevented thymidine production leading to misincorporation of uracil into DNA and replication stress. Overall, these results demonstrate a functional link between MTHFD2-dependent cancer metabolism and replication stress that can be exploited therapeutically with this new class of inhibitors.

Citing Articles

Senescence Reprogramming by MTHFD2 Deficiency Facilitates Tumor Progression.

Fang Z, Pei W, Wu Q, Niu T, Dong C, Wu M J Cancer. 2024; 15(20):6577-6593.

PMID: 39668825 PMC: 11632999. DOI: 10.7150/jca.99168.

Development of Potent and Selective Inhibitors of Methylenetetrahydrofolate Dehydrogenase 2 for Targeting Acute Myeloid Leukemia: SAR, Structural Insights, and Biological Characterization.

Chang H, Lee L, Hsu T, Peng Y, Huang C, Yeh T J Med Chem. 2024; 67(23):21106-21125.

PMID: 39591507 PMC: 11647893. DOI: 10.1021/acs.jmedchem.4c01775.

Nuclear localization of MTHFD2 is required for correct mitosis progression.

Pardo-Lorente N, Gkanogiannis A, Cozzuto L, Ganez Zapater A, Espinar L, Ghose R Nat Commun. 2024; 15(1):9529.

PMID: 39532843 PMC: 11557897. DOI: 10.1038/s41467-024-51847-z.

Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions.

Flickinger K, Wilson K, Rossiter N, Hunger A, Vishwasrao P, Lee T Sci Adv. 2024; 10(40):eadq3591.

PMID: 39365851 PMC: 11451515. DOI: 10.1126/sciadv.adq3591.

Selectivity analysis of diaminopyrimidine-based inhibitors of MTHFD1, MTHFD2 and MTHFD2L.

Jha V, Eriksson L Sci Rep. 2024; 14(1):21073.

PMID: 39256448 PMC: 11387627. DOI: 10.1038/s41598-024-71879-1.

References

Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C . Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006; 444(7119):638-42. DOI: 10.1038/nature05327. View

Toledo L, Altmeyer M, Rask M, Lukas C, Larsen D, Povlsen L . ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell. 2013; 155(5):1088-103. DOI: 10.1016/j.cell.2013.10.043. View

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

Hussain T, Mulherkar R . Lymphoblastoid Cell lines: a Continuous in Vitro Source of Cells to Study Carcinogen Sensitivity and DNA Repair. Int J Mol Cell Med. 2014; 1(2):75-87. PMC: 3920499. View

Shin M, Bryant J, Momb J, Appling D . Mitochondrial MTHFD2L is a dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase expressed in both adult and embryonic tissues. J Biol Chem. 2014; 289(22):15507-17. PMC: 4140906. DOI: 10.1074/jbc.M114.555573. View

Yang M, Vousden K . Serine and one-carbon metabolism in cancer. Nat Rev Cancer. 2016; 16(10):650-62. DOI: 10.1038/nrc.2016.81. View

Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E . ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood. 2015; 127(5):582-95. DOI: 10.1182/blood-2015-05-644872. View

Petermann E, Orta M, Issaeva N, Schultz N, Helleday T . Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell. 2010; 37(4):492-502. PMC: 2958316. DOI: 10.1016/j.molcel.2010.01.021. View

Maya-Mendoza A, Moudry P, Merchut-Maya J, Lee M, Strauss R, Bartek J . High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018; 559(7713):279-284. DOI: 10.1038/s41586-018-0261-5. View

10.

Parkhurst J, Winter G, Waterman D, Fuentes-Montero L, Gildea R, Murshudov G . Robust background modelling in . J Appl Crystallogr. 2016; 49(Pt 6):1912-1921. PMC: 5139990. DOI: 10.1107/S1600576716013595. View

11.

Karawajczyk A, Orrling K, de Vlieger J, Rijnders T, Tzalis D . The European Lead Factory: A Blueprint for Public-Private Partnerships in Early Drug Discovery. Front Med (Lausanne). 2017; 3:75. PMC: 5243859. DOI: 10.3389/fmed.2016.00075. View

12.

. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 5):760-3. DOI: 10.1107/S0907444994003112. View

13.

Mathews C . Deoxyribonucleotide metabolism, mutagenesis and cancer. Nat Rev Cancer. 2015; 15(9):528-39. DOI: 10.1038/nrc3981. View

14.

Pilzecker B, Buoninfante O, van den Berk P, Lancini C, Song J, Citterio E . DNA damage tolerance in hematopoietic stem and progenitor cells in mice. Proc Natl Acad Sci U S A. 2017; 114(33):E6875-E6883. PMC: 5565453. DOI: 10.1073/pnas.1706508114. View

15.

Meiser J, Tumanov S, Maddocks O, Labuschagne C, Athineos D, van den Broek N . Serine one-carbon catabolism with formate overflow. Sci Adv. 2016; 2(10):e1601273. PMC: 5091358. DOI: 10.1126/sciadv.1601273. View

16.

Sarmento L, Povoa V, Nascimento R, Real G, Antunes I, Martins L . CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress. Oncogene. 2014; 34(23):2978-90. DOI: 10.1038/onc.2014.248. View

17.

Nilsson R, Jain M, Madhusudhan N, Gustafsson Sheppard N, Strittmatter L, Kampf C . Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014; 5:3128. PMC: 4106362. DOI: 10.1038/ncomms4128. View

18.

Yap T, Plummer R, Azad N, Helleday T . The DNA Damaging Revolution: PARP Inhibitors and Beyond. Am Soc Clin Oncol Educ Book. 2019; 39:185-195. DOI: 10.1200/EDBK_238473. View

19.

Kawai J, Ota M, Ohki H, Toki T, Suzuki M, Shimada T . Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold. ACS Med Chem Lett. 2019; 10(6):893-898. PMC: 6580548. DOI: 10.1021/acsmedchemlett.9b00069. View

20.

Evans P . Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr. 2005; 62(Pt 1):72-82. DOI: 10.1107/S0907444905036693. View